par Marechal, Raphaël 
;Van Laethem, Jean-Luc
Référence Expert review of anticancer therapy, 9, 10, page (1439-1441)
Publication Publié, 2009-10
;Van Laethem, Jean-Luc Référence Expert review of anticancer therapy, 9, 10, page (1439-1441)
Publication Publié, 2009-10
Article révisé par les pairs
| Résumé : | EVALUATION OF: Costantino CL, Witkiewicz AK, Kuwano Y et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 69, 4567-4572 (2009). Gemcitabine has been the standard of care for pancreatic cancer for a decade but is only effective in some patients. As a prodrug, gemcitabine is activated by different protein kinases. The deoxycytidine kinase (dCK) is the first step of intracellular activation. We review the study by Costantino and colleagues, evaluating the consequence of modulating Hu antigen R (HuR), a stress response protein, on dCK expression and the correlation between HuR expression levels and pancreatic cancer outcome. This study demonstrates that dCK protein concentration levels were regulated by HuR and that a high cytoplasmic HuR level was associated with a sevenfold decreased risk of mortality after resection of pancreatic adenocarcinoma and gemcitabine therapy. |
